Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GENinCode UK Ltd. ( (GB:GENI) ) has issued an update.
GENinCode Plc reported a 25% increase in revenues for FY24, driven by growth in the UK and Europe, and introduced its polygenic tests to the US market. The company received its first US test revenues for its LIPID inCode and CARDIO inCode products, with the latter receiving a US Notice of Allowance for patent status. The NHS expanded the use of LIPID inCode for familial hypercholesterolemia diagnosis, and the CARDIO inCode pilot was launched in Spain. The company also completed a £4.1m secondary placing to support its scale-up and commercialization efforts. For FY25, GENinCode aims to significantly increase revenues, improve margins, and move towards breakeven, with plans for commercial expansion in the US and further development of its NHS and EU programs.
More about GENinCode UK Ltd.
GENinCode Plc is a UK-based company specializing in genetic risk assessment for cardiovascular disease and ovarian cancer. The company operates in the UK, Europe, and the United States, providing predictive technology that combines clinical algorithms and AI bioinformatics to advance patient risk assessment and preventive care strategies.
Average Trading Volume: 598,701
Technical Sentiment Signal: Sell
Current Market Cap: £4.45M
See more insights into GENI stock on TipRanks’ Stock Analysis page.